Frame, S., Saladino, C., MacKay, C., Atrash, B., Sheldrake, P., McDonald, E., . . . Zheleva, D. Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer. Public Library of Science (PLoS).
Chicago Style (17th ed.) CitationFrame, Sheelagh, et al. Fadraciclib (CYC065), a Novel CDK Inhibitor, Targets Key Pro-survival and Oncogenic Pathways in Cancer. Public Library of Science (PLoS).
MLA (9th ed.) CitationFrame, Sheelagh, et al. Fadraciclib (CYC065), a Novel CDK Inhibitor, Targets Key Pro-survival and Oncogenic Pathways in Cancer. Public Library of Science (PLoS).
Warning: These citations may not always be 100% accurate.